Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Fat-free mass index (FFMI), a measure similar to body mass index (BMI) but that also takes into account the amount of muscle mass in the body is a significant ... Read more
Treating idiopathic pulmonary fibrosis (IPF) patients with the anti-IPF drug Esbriet (pirfenidone) before and after lung surgery could be protective against acute exacerbation, or worsening of IPF, a life-threatening ... Read more
The effectiveness of long-term treatment with the anti fibrotic drug Esbriet (pirfenidone) for more than 3 years does not depend on the forced vital capacity (FVC) at baseline in ... Read more
Treatment with Ofev (nintedanib) is associated with stabilization of lung function in patients with idiopathic pulmonary fibrosis (IPF) according to a study published in the scientific journal Respiration.
Researchers are one step closer to understanding the molecular mechanism of action of pirfenidone, the anti fibrotic drug for the treatment of pulmonary fibrosis. This may help improve the ... Read more
Metformin, a first line medication for the treatment of type 2 diabetes, reduces inflammation and pulmonary fibrosis in mice, suggests a study published in the Journal of Korean Medical ... Read more
The U.S. Department of Defense granted $11.5 million to researchers at National Jewish Health, one of the leading respiratory hospitals in the country, for two research projects investigating lung ... Read more
Pulmatrix, a clinical stage biopharmaceutical company, recently released an animated life sciences video describing their new dry powder inhaler system called Isperse for lung disease patients.
OFEV (nintedanib) is effective for a wide range of idiopathic pulmonary fibrosis (IPF) patients according to Boehringer Ingelheim, the company that developed the drug.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more
